AgingResearch.NewsJoin free

Vial

CompanyUnited States

Vial develops one asset, in phase 1 (IL-13 x TSLP in asthma). Mostly antibody acting on TSLP, inflammation and IL13; based in the United States.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1

  • IL-13 x TSLP

    Bispecific antibody targeting IL-13 and TSLP for Type 2 inflammatory airway disease control.

    Phase 1, Antibody, TSLP, Inflammation, asthma

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Similar companies6

Intelligence